Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Total Non-Current Liabilities (2022 - 2025)

Goldenwell Biotech filings provide 4 years of Total Non-Current Liabilities readings, the most recent being $125983.0 for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 879.26% to $125983.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $125983.0, a 879.26% increase, with the full-year FY2024 number at $82183.0, up 11.3% from a year prior.
  • Total Non-Current Liabilities hit $125983.0 in Q3 2025 for Goldenwell Biotech, down from $148883.0 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $148883.0 in Q2 2025 to a low of -$20366.0 in Q1 2024.
  • Median Total Non-Current Liabilities over the past 4 years was $29126.0 (2022), compared with a mean of $39129.5.
  • Biggest five-year swings in Total Non-Current Liabilities: tumbled 1544.4% in 2024 and later soared 915.04% in 2025.
  • Goldenwell Biotech's Total Non-Current Liabilities stood at $20000.0 in 2022, then soared by 269.18% to $73837.0 in 2023, then increased by 11.3% to $82183.0 in 2024, then soared by 53.3% to $125983.0 in 2025.
  • The last three reported values for Total Non-Current Liabilities were $125983.0 (Q3 2025), $148883.0 (Q2 2025), and $84283.0 (Q1 2025) per Business Quant data.